AstraZeneca (AZN) stock surged early Thursday after the pharma company reported core earnings of $2.09 per share on $14.89 billion in fourth-quarter sales.
↑ X NOW PLAYING How To Buy Stocks: IBD's Four Pillars Of InvestingBoth measures beat expectations, according to FactSet. Earnings rocketed 44% on a strict, as-reported basis, while sales climbed 24%.
For the year, AstraZeneca guided to sales growth in the high single-digit percentage range. The company also projects core earnings growth at a low double-digit percentage. Wall Street projected earnings of $9.27 per share on $56.79 billion in sales.
In premarket trades on the stock market today, AstraZeneca stock jumped more than 4.5% to 74.17.
More to follow.
YOU MAY ALSO LIKE:
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
Merck Stock Plummets 9% As Gardasil Dynamics, 2025 Guidance Weigh On Shares
Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists
Want More IBD Insights? Subscribe To Our Investing Podcast!
Get Timely Buy & Sell Alerts With IBD Leaderboard
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。